{
    "nct_id": "NCT03800836",
    "official_title": "A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer",
    "inclusion_criteria": "General:\n\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Adequate hematologic and organ function.\n* For Cohorts 1, 2 and 4: Life expectancy of at least 6 months.\n* For men and women of child bearing potential: agreement to remain abstinent or use protocol defined contraceptive measures during the treatment period and for at least 28 days after the last dose of ipatasertib, 6 months after the last dose of paclitaxel, nab-paclitaxel, or doxorubicin, and 12 months after the last dose of cyclophosphamide, and 5 months after the last dose of atezolizumab, whichever occurs later along with refraining from donating sperm or eggs during this same period.\n\nDisease-specific:\n\n* For Cohorts 1, 2 and 4: histologically documented TNBC that is locally advanced or metastatic and is not amenable to resection with curative intent.\n* For Cohort 2: disease progression following one or two lines of systemic therapy for inoperable locally advanced or metastatic TNBC.\n* For Cohorts 1, 2 and 4: measurable disease according to RECIST v1.1 criteria.\n* For Cohort 2: Treated brain or spinal cord metastases are allowed if participants have stable disease and are not on steroid treatment.\n* For Cohort 3: histologically documented TNBC with a primary breast tumour size of > 2 cm by at least one radiographic or clinical measurement and disease stage at presentation of cT2-4 cN0-3 cM0.\n* For Cohort 3: participant agreement to undergo appropriate surgical management, including axillary lymph node surgery and partial or total mastectomy, after completion of neoadjuvant treatment.\n* For Cohort 4: participants must have centrally confirmed PD-L1-positive tumour.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "General:\n\n* History of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills.\n* Active infection requiring antibiotics.\n* History of or current evidence of HIV infection.\n* Known clinically significant history of liver disease.\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or anticipation of need for a major surgical procedure (other than anticipated breast surgery for Cohort 3) during the course of the study.\n* Pregnant or breastfeeding.\n* New York Heart Association (NYHA) Class II, III, or IV heart failure; left ventricular ejection fraction < 50%; or active ventricular arrhythmia requiring medication.\n* Treatment with approved or investigational cancer therapy within 14 days prior to Day 1 of Cycle 1.\n* Prior treatment with an Akt inhibitor.\n\nDisease-specific:\n\n* For Cohorts 1 and 4: history of or known presence of brain or spinal cord metastases.\n* For Cohorts 1 and 4: participants who have received previous systemic therapy for inoperable locally advanced or metastatic TNBC, including chemotherapy, immune checkpoint inhibitors, or targeted agents.\n* Unresolved, clinically significant toxicity from prior therapy, except for alopecia and Grade 1 peripheral neuropathy.\n* Participants who have received palliative radiation treatment to peripheral sites (e.g., bone metastases) for pain control and whose last treatment was completed 14 days prior to Day 1 of Cycle 1 and have recovered from all acute, reversible effects.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites.\n* Uncontrolled tumor related complications.\n* Uncontrolled hypercalcaemia or symptomatic hypercalcaemia requiring continued use of bisphosphonate therapy.\n* Malignancies other than breast cancer within 5 years prior to Day 1 of Cycle 1.\n* For Cohort 3, participants with the following are excluded: [1] prior history of invasive breast cancer; [2] prior systemic therapy for treatment and/or prevention of invasive breast cancer; [3] previous therapy with anthracyclines or taxanes for any malignancy; [4] bilateral breast cancer; [5] undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes; [6] undergone axillary lymph node dissection (ALND) prior to initiation of neoadjuvant therapy; [6] history of other malignancy within 5 years prior to screening; [7] history of cerebrovascular accident within 12 months prior to initiation of study treatment; [8] cardiopulmonary dysfunction; [9] known allergy or hypersensitivity to the components of cyclophosphamide/doxorubicin formulations and filgrastim or pegfilgrastim formulations; [10] severe infection within 4 weeks prior to initiation of study treatment; [11] treatment with therapeutic oral or IV (Intravenous) antibiotics within 2 weeks prior to initiation of study treatment and [12] prior treatment with CD137 agonists or immune checkpoint - blockade therapies.\n\nIpatasertib-specific:\n\n* History of Type I or Type II diabetes mellitus requiring insulin.\n* Grade >= 2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia.\n* History of or active inflammatory bowel disease or active bowel inflammation.\n* Clinically significant lung disease.\n* Treatment with strong CYP3A inhibitors or strong CYP3A inducers.\n\nAtezolizumab-specific:\n\n* Active or history of autoimmune disease or immune deficiency.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.\n* Prior allogeneic stem cell or solid organ transplantation.\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during treatment with atezolizumab or within 5 months after the last dose of atezolizumab.\n* History of hypersensitivity reactions to study drug or any component of the study drug formulation.\n* Treatment with systemic immunostimulatory agents and immunosuppressive medication treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study.\n\nPaclitaxel-specific:\n\n- Grade >= 2 peripheral neuropathy.",
    "miscellaneous_criteria": ""
}